JAGX
Price
$3.99
Change
+$0.09 (+2.31%)
Updated
Jun 6, 04:21 PM (EDT)
Capitalization
4.97M
QLGN
Price
$3.74
Change
-$0.07 (-1.84%)
Updated
Jun 6, 11:43 AM (EDT)
Capitalization
2.81M
Interact to see
Advertisement

JAGX vs QLGN

Header iconJAGX vs QLGN Comparison
Open Charts JAGX vs QLGNBanner chart's image
Jaguar Health
Price$3.99
Change+$0.09 (+2.31%)
Volume$280
Capitalization4.97M
Qualigen Therapeutics
Price$3.74
Change-$0.07 (-1.84%)
Volume$100
Capitalization2.81M
JAGX vs QLGN Comparison Chart
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. QLGN commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and QLGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (JAGX: $3.93 vs. QLGN: $3.81)
Brand notoriety: JAGX and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 31% vs. QLGN: 5%
Market capitalization -- JAGX: $4.97M vs. QLGN: $2.81M
JAGX [@Biotechnology] is valued at $4.97M. QLGN’s [@Biotechnology] market capitalization is $2.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 0 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • JAGX’s FA Score: 0 green, 5 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 3 TA indicator(s) are bullish while QLGN’s TA Score has 3 bullish TA indicator(s).

  • JAGX’s TA Score: 3 bullish, 6 bearish.
  • QLGN’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, QLGN is a better buy in the short-term than JAGX.

Price Growth

JAGX (@Biotechnology) experienced а -14.94% price change this week, while QLGN (@Biotechnology) price change was +0.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

JAGX is expected to report earnings on Mar 31, 2025.

QLGN is expected to report earnings on Mar 01, 2023.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAGX($4.97M) has a higher market cap than QLGN($2.81M). JAGX has higher P/E ratio than QLGN: JAGX (0.01) vs QLGN (0.00). QLGN YTD gains are higher at: -9.501 vs. JAGX (-84.436). QLGN has higher annual earnings (EBITDA): -6.73M vs. JAGX (-29.1M). JAGX has more cash in the bank: 13.3M vs. QLGN (388K). QLGN has less debt than JAGX: QLGN (1.43M) vs JAGX (34.3M). JAGX has higher revenues than QLGN: JAGX (10.5M) vs QLGN (0).
JAGXQLGNJAGX / QLGN
Capitalization4.97M2.81M177%
EBITDA-29.1M-6.73M432%
Gain YTD-84.436-9.501889%
P/E Ratio0.010.00882%
Revenue10.5M0-
Total Cash13.3M388K3,428%
Total Debt34.3M1.43M2,392%
FUNDAMENTALS RATINGS
JAGX vs QLGN: Fundamental Ratings
JAGX
QLGN
OUTLOOK RATING
1..100
5117
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9858
P/E GROWTH RATING
1..100
10046
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (27) in the null industry is in the same range as JAGX (37) in the Pharmaceuticals Generic industry. This means that QLGN’s stock grew similarly to JAGX’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that QLGN’s stock grew similarly to JAGX’s over the last 12 months.

JAGX's SMR Rating (99) in the Pharmaceuticals Generic industry is in the same range as QLGN (100) in the null industry. This means that JAGX’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's Price Growth Rating (58) in the null industry is somewhat better than the same rating for JAGX (98) in the Pharmaceuticals Generic industry. This means that QLGN’s stock grew somewhat faster than JAGX’s over the last 12 months.

QLGN's P/E Growth Rating (46) in the null industry is somewhat better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that QLGN’s stock grew somewhat faster than JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXQLGN
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTNB0.880.05
+5.67%
Matinas Biopharma Holdings Inc
RDY15.530.78
+5.29%
Dr. Reddy's Laboratories Ltd
PATK90.633.78
+4.35%
Patrick Industries Inc
FCBC37.580.10
+0.27%
First Community Bankshares
MPTI44.76-1.39
-3.01%
M-tron Industries

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and DVHGF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and DVHGF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-1.75%
DVHGF - JAGX
27%
Poorly correlated
N/A
SNPX - JAGX
26%
Poorly correlated
+3.19%
SLNO - JAGX
26%
Poorly correlated
-2.47%
ACET - JAGX
26%
Poorly correlated
-5.25%
NCNA - JAGX
26%
Poorly correlated
-14.75%
More